ABSTRACT: Vitamin D receptor (VDR) is a member of the nuclear hormone receptor superfamily. When bound to a variety of vitamin D analogues, VDR manifests a wide diversity of physiological actions. The molecular mechanism by which different vitamin D analogues cause specific responses is not understood. . Ligand-specific chemical shifts mapped not only to residues at or near the binding pocket but also to residues remote from the ligand binding site. The complexes of rVDR-LBD with native hormone and the potent agonist 2MD exhibited chemical shift differences in signals from helix-12, which is part of the AF2 transactivation domain that appears to play a role in the selective recruitment of coactivators. By contrast, formation of the complex of rVDR-LBD with the antagonist OU-72 led to disappearance of signals from residues in helices-11 and -12. We present evidence that disorder in this region of the receptor in the antagonist complex prevents the attachment of coactivators. V itamin D receptor (VDR) belongs to the type II class of nuclear hormone receptor superfamily, which comprises proteins that share a common structural architecture and are localized in the cell nucleus.
V itamin D receptor (VDR) belongs to the type II class of nuclear hormone receptor superfamily, which comprises proteins that share a common structural architecture and are localized in the cell nucleus.
1 1α,25-Dihydroxyvitamin D 3 [1,25(OH) 2 D 3 ], the natural hormone that interacts with VDR, has been investigated in clinical treatment of divergent diseases including osteoporosis, cancers, autoimmune dysfunctions, cardiovascular diseases, and infections.
2−4 A recent study of the human genome sequence suggested that VDR binds to more than 2700 sites on the DNA and affects the expression levels of at least 229 gene products in response to vitamin D3. 5 Many analogues of 1,25(OH) 2 D 3 have been prepared in an attempt to target specific actions of vitamin D. 6 VDR exhibits a wide diversity of physiological activities when bound to different vitamin D analogues; however, the molecular mechanism behind the ability of different vitamin D analogues to cause this diversity is yet to be elucidated.
Nuclear receptor ligand binding domains (LBDs) are known to undergo conformational changes upon binding of their physiological ligands, and this has been termed the "mouse trap" model. 7 Crystallographic and solution NMR studies of retinoid X receptor (RXR) α and peroxisome proliferatoractivated receptor (PPAR) showed that they undergo conformational changes upon binding 9-cis-retinoic acid and rosiglitazone, respectively. 8, 9 VDR contains two independent transactivation function (AF) domains: AF-1 located in the N-terminal region and AF-2 in the C-terminal or ligand binding region. The action of liganded VDR is mediated through heterodimerization with RXR and binding to vitamin D responsive elements found in the promoter and other target gene domains. This complex then binds coactivators and/or corepressors leading to activation/repression of target genes. 10 In the agonist-bound LBD structure, the AF-2 domain (consisting of helix-12) adopts a conformation (agonist conformation) allowing recruitment of coactivators, whereas in the antagonist bound LBD structure, the AF-2 domain adopts a different conformation (antagonist conformation) that prevents binding of coactivators, thereby preventing transcription.
11 −16 It has been proposed that the differential biological activities of vitamin D analogues result from their stabilization of different VDR conformations. Nevertheless, no significant differences were observed in the conformation of the protein in crystal structures of complexes with ligands having very different biological activities. 17−19 Similar results were obtained in X-ray studies of the retinoic acid receptor, which exhibited the same protein conformation when bound to ligands differing in biological activity. 20, 21 In both cases crystal packing forces apparently preserved the protein conformation and led to distortion of the ligand geometries.
Our hypothesis was that in solution, in the absence of crystal packing constraints, differences in the conformation of the VDR receptor when bound to diverse ligands should be observable by NMR spectroscopy. We selected a well-studied system, the vitamin D ligand binding domain construct of Rattus norvegicus (rVDR 116−423, Δ165−211) (rVDR-LBD) previously studied by X-ray crystallography, 17 and investigated its conformation when bound to three ligands with different structures ( Figure 1 ) and divergent biological effects:
1,25(OH) 2 D 3 , the natural agonist; 2MD, a synthetic analogue that has been shown to increase bone Ca 2+ resorption by 30-fold in vivo and by 2 orders of magnitude in vitro; 22 and OU-72, a potent antagonist that inhibits the transcription of 1,25(OH) 2 D 3 -activated genes in vitro. Crystal structures solved for the complexes of rVDR-LBD bound to 1,25(OH) 2 D 3 (PDB id: 1RK3) and 2MD (PDB id: 1RJK) were found to have identical protein conformations, 17 and attempts to crystallize the complex containing OU-72 were unsuccessful. Here we report assigned NMR chemical shifts of rVDR-LBD when bound to these three ligands and document chemical shift differences that report on the differential influence of these ligands on the solution conformation of the protein. 15 N]-ISOGRO (5 g/L) for double labeling. The yield from the 200 mL culture was 4 mg of labeled VDR-LBD. The inclusion bodies were solubilized in 6 M guanidinium chloride and refolded by dialysis against a buffer containing 20 mM NaH 2 PO 4 −Na 2 HPO 4 (pH 7.4), 50 mM KCl, and 2 mM DTT. The rVDR-LBD was purified to apparent homogeneity as analyzed by 12% SDS-PAGE. Aliquots of the pure labeled rVDR-LBD protein were incubated with desired ligands at 3−4-fold molar excess and concentrated to a final concentration of ∼0.5 mM in a buffer containing 20 mM NaH 2 PO 4 −Na 2 HPO 4 (pH 7.4), 50 mM KCl, 5 mM DTT, 5X protease inhibitor (Roche), 0.05% NaN 3 , and 7% D 2 O. A 4-fold molar excess of the 13-residue peptide from DRIP205, which contains the LxxLL motif mimicking the coactivator, was added and incubated for 2 h at 4°C. The protein concentration was determined by the Bradford method using bovine serum albumin as the standard. The ligand binding activity of LBD for all three ligands was confirmed with a competition assay as previously described. These magnitudes were used to color code the residues showing differences on the three-dimensional crystal structure of rVDR-LBD complexed to 1,25(OH) 2 D 3 (PDB id: 1RK3). PyMol 31 software was used for structure analysis and graphical display.
■ MATERIALS AND METHODS

Production
■ RESULTS
Stable isotope-labeled rVDR-LBD samples were produced and purified as recombinant protein in Escherichia coli cells. NMR spectra were recorded using TROSY-based pulse sequences on 900 or 600 MHz NMR spectrometers equipped with cryogenic probes regulated at the temperatures indicated.
The two-dimensional transverse relaxation Comparison of the assigned TROSY-NHSQC spectra of the two agonist complexes (Figure 6a ) revealed many small but significant chemical shift differences (Figure 7 ). Although these chemical shift differences were found globally, the major differences involved residues in the ligand binding pocket and reflected changes in the interfaces between the two ligands and the protein. In particular, the largest chemical shift differences mapped to residues in secondary structural elements, including helices-3, 5, 6, 7, 10, 11, 12 and the β-sheet and indicated that the largest structural changes are centered on residues V230 and I234 from helix-3. A similar comparison of the spectra of the 1,25(OH) 2 D 3 complex with those of the OU-72 complex (Figure 6b ) revealed a number of large chemical shift differences (indicated by arrows in the figure). In addition, peaks from several residues observed in the 1,25(OH) 2 D 3 complex (circled in red) were absent in the OU-72 complex. The chemical shift differences between these two complexes are shown in Figure 8 . We have mapped the chemical shift differences onto the X-ray structure of the ternary rVDR-LBD-1,25(OH) 2 D 3 -LxxLL peptide complex ( Figure 9 ). DRIP205 is a known coactivator of VDR, and a helical fragment of this protein containing the consensus sequence LxxLL (KNHPMLMNLLKDN-NH 2 ) has been shown to be responsible for transactivation of VDR in vivo as well as in vitro. 33 Binding of this LxxLL-containing peptide to [U-2 H,U- 11029 chemical shift differences. Those from residues in or near the ligand binding pocket could, in principle, only reflect differential interactions with the ligands, but those from residues remote from the binding pocket are indicative of ligand-induced conformational changes. Secondary structural elements predicted by the PECAN, 27 TALOS+, 28 and CSI 29 programs for rVDR-LBD in the 1,25(OH) 2 D 3 complex were in agreement with one another; the positions of the 12 α-helices and 3 short β-strands predicted by these programs are compared in Figure 5 with the 13 
C
α secondary chemical shifts calculated by CYANA. 35 Addition of the LxxLL-containing peptide corresponding to the helical fragment from the coactivator DRIP205 to the rVDR-LBD-1,25(OH) 2 D 3 complex resulted in small but significant chemical shift changes for amide peaks in the TROSY-NHSQC spectrum, confirming that the peptide binds to this complex (Figure 10a ). By contrast, signals from the rVDR-LBD-OU-72 complex did not show appreciable chemical shift changes upon addition of the LxxLL peptide, suggesting that the peptide does not bind under these conditions (Figure 10b) . The rVDR-LBD-OU-72 complex may lack a stable binding surface for the peptide because of the conformational dynamics observed in the AF-2 domain.
The molecular mechanism of action of antagonist-bound nuclear receptors is significantly different from that of the agonist-bound receptors. In the estrogen receptor (ERα), it has been shown that binding of the antagonists raloxifen or tamoxifen causes movement of the ERα AF-2 domain preventing coactivator binding. 15, 16 This suggests that the activation and inhibition of gene transcription utilize different molecular mechanisms. In the case of VDR, OU-72 has been identified as a potential antagonist that inhibits the transcription of several gene targets. rVDR-LBD complexed with OU-72 exhibited a high quality TROSY-NHSQC spectrum with significant and global spectral (structural) differences from that of the rVDR-LBD complex with 1,25(OH) 2 D 3 (Figure 4 ). Apart from changes in the chemical shifts of residues in the ligand binding site, the most striking difference was the absence of amide peaks corresponding to residues 395−421 in the spectrum of the OU-72 complex ( Figure 6 ). An explanation for the absence of these resonances (corresponding to residues colored pink in Figure 9 ) is that residues in helices-11 and -12 are structurally dynamic and visit two or more conformations at exchange rates on the intermediate NMR time scale where signals are broadened beyond detection. This result, which indicates that the AF2 The finding that rVDR-LBD complexes with ligands and coactivators causing diverse physiological responses exhibit distinct spectral signatures demonstrates that NMR spectroscopy offers a powerful platform for the systematic study of this important member of the nuclear hormone receptor superfamily. Studies are underway aimed at determining the solution structures of the complexes described here. 
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